Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Bibliographic Details
Title: Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Authors: Wang, Eunice S *, *, Issa, Ghayas C *, Erba, Harry P, Altman, Jessica K, Montesinos, Pau, DeBotton, Stephane, Walter, Roland B, Pettit, Kristen, Savona, Michael R, Shah, Mithun Vinod, Kremyanskaya, Marina, Baer, Maria R, Foran, James M, Schiller, Gary, Adès, Lionel, Heiblig, Mael, Berthon, Celine, Peterlin, Pierre, Rodríguez-Arbolí, Eduardo, Salamero, Olga, Patnaik, Mrinal M, Papayannidis, Cristina, Grembecka, Jolanta, Cierpicki, Tomasz, Clegg, Bradley, Ray, Joshua, Linhares, Brian M, Nie, Kun, Mitra, Amitava, Ahsan, Julie Mackey, Tabachri, Marilyn, Soifer, Harris S, Corum, Daniel, Leoni, Mollie, Dale, Stephen, Fathi, Amir T
Source: In The Lancet Oncology October 2024 25(10):1310-1324
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(24)00386-3
Published in:The Lancet Oncology
Language:English